Introduction
Endometrial cancer is the most frequently diagnosed malignancy of the female genital tract. According to the NCI (National Cancer Institute), endometrial cancer is the most common type of gynecological cancer. In the United States, B41 200 cases are diagnosed and B7350 women die from the disease each year (Jemal et al., 2006) . The majority of endometrial cancers (B90%) are adenocarcinomas, which originate in uterine epithelial cells. All endometrial cancers can be further delineated into two types (Deligdisch and Holinka, 1987; Di Cristofano and Ellenson, 2007) . Type I endometrial cancers are estrogen (E2) dependent and appear mostly in pre-and peri-menopausal women. These cancers frequently show mutations in DNA-mismatch repair genes (such as MLH1, MSH2, MSH6), phosphatase and tensin homolog deleted from chromosome 10 (PTEN), K-ras and b-catenin (Di Cristofano and Ellenson, 2007) . In contrast, type II endometrial cancers are E2 independent and are diagnosed mostly in post-menopausal women, thin and fertile women, or in women with normal menstrual cycles.
PTEN is one of the most frequently mutated tumorsuppressor genes in human cancers (Steck et al., 1997) . PTEN is completely lost or mutated in 450% of primary endometrioid endometrial cancers (Sun et al., 2001 ) and in at least 20% of endometrial hyperplasias, the precancerous lesions of the endometrium (Levine et al., 1998; Sun et al., 2001) . Thus, the loss of PTEN is a very early event in the multistep process leading to endometrioid endometrial cancer. PTEN functions as a negative regulator of phosphoinositide 3-kinase (PI3K) signaling, which regulates a number of cellular functions through the activation of Akt (Jiang and Liu, 2008) . Previously, the loss of Pten (either as a heterozygote or by uterine-specific ablation) has been shown to induce endometrial cancer in mice highlighting its important role in endometrial cancer development (Vilgelm et al., 2006; Daikoku et al., 2008) . This mutation and subsequent Akt activation resulted in the activation of estrogen receptor-a-dependent pathways, which have an important role in endometrial cancer tumorigenesis (Vilgelm et al., 2006) . Interestingly, the PI3K signaling pathway can also be activated by E2, suggesting that a complex interaction exists between these two signaling pathways (Chambliss et al., 2002) .
Mig-6 is an immediate early response gene that can be induced by various mitogens and commonly occurring chronic stress stimuli (Makkinje et al., 2000; Saarikoski et al., 2002) . It is an adaptor molecule containing a CRIB domain, a src homology 3 (SH3) binding domain, a 14-3-3 binding domain and an EGFR (epidermal growth factor receptor)-binding domain, but no domain with enzymatic activity (Burbelo et al., 1995; Makkinje et al., 2000) . Previously, the interaction between MIG-6 and the 14-3-3 proteins has been demonstrated (Makkinje et al., 2000) . Ablation of Mig-6 in mice leads to the development of animals with epithelial hyperplasia, adenoma and adenocarcinomas in organs, such as the uterus, lung, gallbladder and bile duct (Anastasi et al., 2005; Ferby et al., 2006; Zhang et al., 2006; Jin et al., 2007; Jeong et al., 2009) . Decreased expression of Mig-6 is observed in human breast carcinomas, which correlate with reduced overall survival of patients with breast cancer (Amatschek et al., 2004; Anastasi et al., 2005) . These data point to Mig-6 as a tumor-suppressor gene in both mice and humans. Previously, we showed that the absence of Mig-6 in mice results in the inability of P4 to inhibit E2-induced uterine weight gain and expression of E2-responsive target genes (Jeong et al., 2009) .
) mice develop hyperplasia and endometrial cancer in a hormone-dependent manner. In addition, the observation that endometrial carcinomas from women have a significant reduction in MIG-6 expression provides compelling support for an important growth regulatory role for Mig-6 in the uterus of both humans and mice (Jeong et al., 2009) . This demonstrates that Mig-6 is a critical regulator of the tumorigenesis of endometrial cancer. However, the mechanism of Mig-6 action in endometrial cancer remains unknown.
In this study, we used conditional Pten and Mig-6 ablation in the uteri of mice to demonstrate a synergistic effect of dysregulation of the Pten and Mig-6 signaling pathways during endometrial tumorigenesis. Ablation of both genes dramatically accelerated the development of endometrial cancer compared with the single mutation of either gene. Thus, these results demonstrate the importance of Pten and Mig-6 regulation in the tumorigenesis of endometrial cancer by promoting epithelial cell apoptosis.
Results
Generation of mice with Pten and Mig-6 ablation in the murine uterus The most common genetic mutations in human endometrioid carcinoma are found in the Pten gene (Podsypanina et al., 1999; Di Cristofano and Ellenson, 2007) . Pten þ /À and mice with Pten conditionally ablated in the uterus (PR
) develop endometrioid endometrial adenocarcinoma Daikoku et al., 2008) . To investigate the effects of the MIG-6 and the PTEN/PI3K/AKT signaling pathways on uterine tumorigenesis, mice with Pten floxed (Pten f/f ) (Lesche et al., 2002) and Mig-6 floxed (Mig-6 f/f ) (Jin et al., 2007) were bred to the PR Cre mouse model (Soyal et al., 2005) (Figure 1a ). There was no effect on Mig-6 expression by Pten ablation. The expression of Pten mRNA was detected in the control, but not in the (Figures 1c and d) . Ablation of Pten also resulted in increased activation of AKT as expected ( Figure 1c ). These results suggest that PR cre efficiently ablated Pten and Mig-6 in the mouse uterus.
Endometrial cancer development in mice with Pten and Mig-6 ablation in PR-expressing cells Previously, ablation of Pten in the uterus was shown to decrease survival due to the development of endometrial cancer (Daikoku et al., 2008 mice at 2 months of age (Daikoku et al., 2008) . Although endometrial hyperplasia and adenocarcinoma were observed, myometrial hyperplasia was not observed in the uteri of Mig-6 (Figure 2g ), diaphragmatic skeletal muscle (Figure 2h ), lymph node, colon and pancreas. These results suggest that Mig-6 has an important role as a tumor suppressor of the development of endometrial cancer caused by Pten ablation. d ). There was also no difference in stromal cell proliferation and apoptosis. These results suggest that Mig-6 functions as a tumor suppressor to induce apoptosis when Pten is mutated.
Mig-6 represses Birc1 expression in the murine uterus
The decision as to whether a cell undergoes apoptosis is determined by the opposing actions of proapoptotic and antiapoptotic effectors (Song and Santen, 2003) . It is known that E2 can tip this balance toward cell survival in uterine epithelial cells by inducing the expression of baculoviral inhibitors of apoptosis repeat-containing 1 (Birc1), a family of antiapoptotic proteins (Yin et al., 2008) . To determine whether Mig-6 promotes uterine epithelial apoptosis by suppressing Birc1 expression, the expression of Birc1a, Birc1b and Birc1e was determined in Mig-6 f/f and Mig-6 d/d mice treated with E2 for 3 days by real-time RT-PCR (n ¼ 3). Interestingly, the expression of Birc1 genes was significantly increased in Mig-6 The interaction of MIG-6 with ERK2 and its regulation of ERK2 phosphorylation Although these results have established the role of Mig-6 in steroid hormone regulation and tumorigenesis, the molecular mechanism of Mig-6 action remains unclear. As MIG-6 is an adaptor molecule, we turned to a biochemical and proteomics approach to identify MIG-6-associating proteins to gain insight into its mechanism of action. One of the hallmarks of endometrial cancer is the loss of ovarian steroid hormone (E2 and P4) control over uterine epithelial cell proliferation and apoptosis (Ito et al., 2007; Franco et al., 2008) . E2 promotes endometrial cancer by stimulating proliferation and inhibiting apoptosis, whereas P4 antagonizes these actions of E2 in the uterus. Our previous results showed that the absence of Mig-6 in mice results in the inability of P4 to inhibit E2-induced uterine weight gain and E2-responsive target genes expression (Jeong et al., 2009) . These results suggest that Mig-6 suppresses E2 signaling in the presence of P4. Therefore, we isolated endogenous MIG-6 protein complexes using an anti-MIG-6 antibody (Sigma-Aldrich, St Louis, MO, USA) from the uteri of Mig-6 f/f and Mig-6 d/d mice treated with E2 þ P4 for 3 days and identified associated proteins using mass spectrometry. Proteins that were identified from lysates prepared by immunoprecipitation in Mig-6 f/f mice but not in Mig-6 d/d mice were considered true interacting proteins. The use of the Mig-6 d/d tissue serves as the control for nonspecific and cross-reacting proteins. Using this criterion, the identified MIG-6-interacting proteins are listed in Table 1 .
The 14-3-3 proteins are known MIG-6-associating proteins (Zhang and Vande Woude, 2007 ) that regulate The role of Mig-6 and Pten in endometrial cancer TH Kim et al the phosphorylation of proteins involved in PTEN/ PI3K/AKT signaling (Kakinuma et al., 2008; Slaets et al., 2008) . We also found novel MIG-6-associated molecules, such as signal transducer and activator of transcription 3, extracellular signal-regulated kinase 2 (ERK2) and growth factor receptor-bound protein 2. ERK2 is a classical mitogen-activated protein kinase that is activated mainly by growth factors or mitogenic stimuli. It is activated by phosphorylation that results in its translocation into the nucleus where it phosphorylates transcription factors (Eldredge et al., 1994; Fukuda et al., 1997) . It has been reported that ERK affects apoptosis by promoting the expression of inhibitor of apoptosis proteins (Xia et al., 1995; Erhardt et al., 1999; Tashker et al., 2002) . To validate the interaction between MIG-6 and ERK2 proteins, we conducted coimmunoprecipitation experiments using lysates from the uteri of Mig-6 f/f and Mig-6 d/d mice treated with E2 þ P4 for 3 days. Coimmunoprecipiatation was performed with anti-IgG, anti-MIG-6 and anti-ERK2 antibodies, and analyzed by western blot analysis using anti-ERK2 antibodies to detect ERK2. The ERK2 protein could be detected from immunoprecipitates with the anti-MIG-6 and anti-ERK2 antibodies confirming the interaction between MIG-6 and ERK2 (Figure 5a ). These results indicate that the interaction between MIG-6 and ERK2 may have an important role in the regulation of the phosphorylation of ERK2 and subsequent regulation of apoptosis.
To determine whether the hyperplasia phenotypes observed may be due to altered ERK2 phosphorylation in the Mig-6 f/f uteri, we examined the expression of ERK2 by western blot analysis in the Mig-6 f/f uteri at 5 months of age. The level of phospho-ERK2 but not (Figure 5d ). These results suggest that Mig-6 has a tumor suppressor function in the context of Pten ablation by promoting epithelial cell apoptosis and by inhibiting ERK2 phosphorylation.
Discussion
Endometrial cancer is the most common gynecological cancer and has been shown to be associated with mutations in the tumor suppressor gene Pten among Daikoku et al., 2008) . This mutation and subsequent Akt activation have an important role in the tumorigenesis of endometrial cancer (Vilgelm et al., 2006) . The expression of MIG-6 is decreased in human endometrial cancer patients and Mig-6 d/d mice develop invasive endometrioid-type endometrial adenocarcinoma with unopposed estrogen treatment (Jeong et al., 2009 (Figure 2) . The neoplastic endometrial glands in double mutant mice invaded through the uterine muscle wall and, with age, led to the development of distant metastases. These results suggest that the tumor suppressor function of Mig-6 is important to prevent the development of Most endometrial cancers are characterized by actively proliferating glands, increased Akt signaling and decreased apoptosis (Khalifa et al., 1994; Sivridis and Giatromanolaki, 2004; Ejskjaer et al., 2007) . The loss of Pten in the uteri of mice and humans results in increased epithelial proliferation (Figures 3a and b) , increased phosphorylation of Akt ( Figure 1c ) and altered E2 signaling Vilgelm et al., 2006; Daikoku et al., 2008) , as well as the development of endometrioid endometrial cancer (Kanamori et al., 2001; Daikoku et al., 2008) . Mig-6 d/d mice exhibit altered E2 signaling (Jeong et al., 2009 ) and a slight but not significant increase in epithelial proliferation (Figures 3a  and b) , with no effect on Akt signaling or epithelial apoptosis. Double mutant mice also have comparable levels of epithelial proliferation (Figures 3a and b) (Figures 3c and d) . As these mice develop endometrial cancer earlier than Pten d/d mice, these data suggest that decreased epithelial apoptosis may contribute to the accelerated tumorigenesis.
As E2 signaling is altered by both Pten and Mig-6 ablation, it suggests that E2 signaling may have a role in the enhanced tumorigenesis of double mutant mice. Estrogen suppresses uterine epithelial apoptosis by inducing BIRC1 expression (Yin et al., 2008) . Birc1 genes encode a family of antiapoptotic proteins, which can physically interact with active caspase-3 and caspase-7 and with active caspase-9 in the presence of ATP (Maier et al., 2002; Davoodi et al., 2004) . The expression of Birc1a, Birc1b and Birc1e is significantly increased in Mig-6 d/d mice treated with E2 ( Figure 4 ). In addition, the expression of Birc1a and Birc1b was significantly increased in Mig-6 d/d Pten d/d mice compared with controls ( Figure 4 ). As these genes are well-known apoptosis inhibitors (Roy et al., 1995; Endrizzi et al., 2000) , their increased expression may contribute to the decreased apoptosis of double mutant mice. Thus, Mig-6 may function as a tumor suppressor in the context of Pten ablation by promoting apoptosis through the expression of the Birc1 family of proteins.
The estrogen receptors mediate the effect of E2 under physiological and pathological conditions either by the activation of E2-target gene transcription (Acconcia and Kumar, 2006) or by nongenomic mechanisms, which result in the rapid activation of several signal transduction pathways to regulate different cellular processes, such as proliferation, apoptosis and differentiation. The nongenomic action of E2 has been linked to numerous pathways (EGFR, insulin-like growth factor-I receptor, c-MET) resulting in the activation of two key signaling cascades, the PTEN/PI3K/AKT and the mitogenactivated protein kinase pathways (Freeman et al., 2006; Vilgelm et al., 2006; Bhat-Nakshatri et al., 2008; Cheskis et al., 2008; Thomas et al., 2008) . One consequence of this nongenomic E2 action is an inhibition of cellular apoptosis, which has been observed in various cell types, such as vascular endothelial, smooth and skeletal muscles, as well as breast cancer cells (Spyridopoulos et al., 1997; Song and Santen, 2003; Bjornstrom and Sjoberg, 2005; Boland et al., 2008) . Mitogen-activated protein kinase/ERK-kinases trigger the activation of ERKs by phosphorylating a threonine and a tyrosine in their activation loop. Specificity in the signaling between these modules is achieved by proteinprotein interactions and scaffolding molecules (Kolch, 2005) . In this study, we identified a novel interaction of MIG-6 with ERK2 and demonstrated that ablation of Mig-6 leads to increased phosphorylation of ERK2 and expression of its target genes ( Figure 5 ). Abnormal or constitutive phosphorylation of ERK2 leads to tumorigenesis through inappropriate suppression of apoptosis (Evan and Vousden, 2001; Lowe et al., 2004) . Thus, these results suggest the Mig-6 may also exert its tumor suppressor function in the context of Pten ablation by regulating the phosphorylation status of ERK2. This increase in phosphorylation may also contribute to the decreased apoptosis observed either by regulating Birc1 expression or by an unknown mechanism. These results suggest that Mig-6 may exert its tumor suppressor function in endometrial cancer by inhibiting ERK2 phosphorylation. Further studies need to be conducted to determine the precise mechanism by which these various pathways are integrated by Mig-6 to regulate epithelial apoptosis during endometrial tumorigenesis, which may lead to the development of additional diagnostics or therapeutics for endometrial cancer.
In conclusion, our results show the synergistic effect of conditional Pten and Mig-6 loss on endometrial cancer development. This accelerated tumorigenesis is likely due to decreased epithelial apoptosis partly through increased expression of the Birc1 family of apoptotic inhibitors and increased phosphorylation of ERK2. This study has established an endometrial cancer mouse model, which replicates common characteristics of the human disease providing a model system to further investigate the genetic and molecular events involved in the transition from normal to hyperplastic/ neoplastic endometrium. These and future results will contribute to the understanding of the molecular mechanism of tumorigenesis and to the development of therapeutic approaches for endometrial cancer.
Materials and methods

Animals and tissue collection
Mice were maintained in the designated animal care facility at the Baylor College of Medicine according to the institutional guidelines for the care and use of laboratory animals. PR Cre/ þ mice were previously generated (Soyal et al., 2005) . Pten f/f were acquired from Dr Hong Wu (University of California, Los Angeles, CA, USA) (Lesche et al., 2002) . Mice of various genotypes were killed at 2 and 4 weeks of age. At the time of dissection, uterine tissues were placed in the appropriate fixative or flash frozen and stored at À80 1C. Statistical analysis for the survival curve was performed using the logrank test.
Western blot analysis Samples containing 15 mg proteins were applied to SDS-PAGE. The separated proteins were transferred onto a polyvinylidene difluoride membrane (Millipore Corp., Bedford, MA, USA). Membranes were blocked overnight with 0.5% casein (wt/vol) in phosphate-buffered saline with 0.1% Tween 20 (vol/vol) (Sigma-Aldrich) and probed with anti-MIG-6 (Sigma-Aldrich; PE-16), anti-PTEN (Cell Signaling Technology Inc., Danvers, MA, USA; #9559), anti-ERK2 (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA; SC-1647), anti-phospho-ERK2 (Santa Cruz Biotechnology Inc.; SC-7883), anti-AKT (Santa Cruz Biotechnology Inc.; SC-55523) or anti-phospho-AKT (Cell Signaling Technology Inc.; #9275S) antibodies. Immunoreactivity was visualized by incubation with a horseradish peroxidase-linked secondary antibody and treatment with ECL reagents. To control for loading, the membrane was stripped and probed with anti-actin (Santa Cruz Biotechnology Inc.; SC-1615) and developed again.
Immunohistochemistry
Uterine sections from paraffin-embedded tissue were preincubated with 10% normal serum in phosphate-buffered saline (pH 7.5) and then incubated with anti-PTEN (Cell Signaling Technology Inc.; #9559), anti-phospho-Histone H3 (Upstate Biotechnology, Lake Placid, NY, USA; 06-570) or anticleaved caspase 3 (Cell Signaling Technology Inc.; #9661L) antibody in 10% normal serum in phosphate-buffered saline (pH 7.5). The next day, sections were washed in phosphatebuffered saline and incubated with a secondary antibody (5 ml/ml; Vector Laboratories, Burlingame, CA, USA) for 1 h at room temperature. Immunoreactivity was detected using the Vectastain Elite ABC kit (Vector Laboratories).
Quantitative real-time RT-PCR Quantitative real-time RT-PCR analysis was conducted on isolated RNA. Expression levels of Mig-6, Pten, Birc1a, Birc1b and Birc1e were measured by real-time RT-PCR TaqMan analysis (Applied Biosystems, Foster City, CA, USA). cDNA was prepared from 1 mg of total RNA using random hexamers and M-MLV Reverse Transcriptase (Invitrogen Corp., Carlsbad, CA). RT-PCR was performed using RT-PCR Universal Master Mix reagent (Applied Biosystems). All real-time RT-PCR results were normalized against 18S RNA using ABI rRNA control reagents. Statistical analyses were performed using one-way ANOVA (analysis of variance), followed by Tukey's post hoc multiple range test with the Instat package from GraphPad (San Diego, CA, USA).
Immuno-affinity purification
We isolated endogenous MIG-6 protein complexes using an anti-MIG-6 antibody (Sigma-Aldrich) from lysate prepared from the uteri of Mig-6 f/f and Mig-6 d/d mice treated with E2 þ P4 for 3 days as previously reported (Jung et al., 2005) . The immunoprecipitates were washed three times with NETN (20 mM Tris-HCl (pH 8.0), 100 mM NaCl, 1 mM EDTA, 0.5% NP-40) and boiled with Laemmli buffer and subjected to SDS-PAGE (4-20% Tris/Glycine NOVEX Gel, Invitrogen Corp.). The Coomassie brilliant blue-stained protein bands were excised and digested in gel with trypsin.
Protein identification
Nano-high performance liquid chromatography/mass spectrometry/mass spectrometry for peptide identification was carried out as described before (Jung et al., 2008 ). An 50 mm Â 75 mm, C18 column (BioBasic C18, 5 mm, 300 Å , PicoFrit, New Objective) was used online with an LTQ mass spectrometer (Finnigan LTQ, ThermoFinnigan, San Jose, CA, USA). The LTQ was operated in the data-dependant mode acquiring fragmentation spectra of the top 20 strongest ions. Obtained mass spectrometry/mass spectrometry spectra were analyzed against modified NCBI-ref protein sequence database using BioWorks database search engine (BioWorksBrowser version 3.2, Thermo Electron, San Jose, CA, USA). All peptide identification with stringent BioWorksBrowser filtering criteriapeptide probability 41 Â 10 À6 and Xcorr score 42.0-was manually examined and all peptides were identified by consecutive b-or y-ions so that false identifications were eliminated.
